Irregularities in the finances of the manufacturer of medical supplies Etropal were found by the audit made by "Active" during check of the report for the previous year. After the auditing procedure unconsolidated loss of the company has increased greatly. There is no full data for deals to the amount of BGN 713 thousand for 2012 and BGN 1.14 milion reported for 2011. Etropal did not settle claims for BGN 25.2 million, as well as duties assessed to BGN 9 thousand. Beside this the company gave a loan to the amount of BGN 605 thousand to an affiliate. The biggest loan that the company gave to affiliates is to the amount of BGN 107 thousand, lent to the subsidiary Syntetica. According to the audited accounts the company had revenues, assessed to BGN 7.89 million, which is a 28% decrease yoy.
Source: Capital (04.04.2013)

Euroins has increased its share in the capital of Synthetica JSC from 149,683 to 155,983 shares, the company informed. After the change, the shareholding Euroins is 5.199% in the share capital of the public company. Synthetica JSC is listed on the Bulgarian Stock Exchange on May 20, 2013. The company is a production holding, consolidating businesses od Plastchim - T JSC, Etropal and is a minority shareholder in Formoplast JSC. Etropal and Formoplast are public companies traded on the Bulgarian Stock Exchange - Sofia.
Source: profit.bg (11.11.2013)